Targeted inhibition of a “signal jammer” protein may improve how tumors respond to immunotherapy. Published today in Nature, a new study demonstrates how some cancer cells use the protein voltage-dependent anion channel 2 (VDAC2) as a signal jammer to prevent the body’s anticancer systems from communicating with the immune system.
Leave A Comment